Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
si-MIR4435-2HG is an experimental small interfering RNA (siRNA) designed to silence the long non-coding RNA (lncRNA) MIR4435-2HG. In hepatocellular carcinoma (HCC), MIR4435-2HG acts as a competitive endogenous RNA (ceRNA) that sponges miR-29c-3p, which normally suppresses the expression of Ferroptosis Suppressor Protein 1 (FSP1). By silencing MIR4435-2HG, this siRNA restores miR-29c-3p activity, leading to the downregulation of FSP1 and the subsequent induction of ferroptosis. This mechanism has been shown to overcome lenvatinib resistance in HCC cells, suggesting its potential as a therapeutic strategy for advanced liver cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on si-MIR4435-2HG.